Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- Alirocumab for treatment of high cholesterol: effectiveness and value : new evidence update1
- Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report1
- Controversies in migraine management: a technology assessment : final report1
- Digital health technologies as an adjunct to medication assisted therapy for opioid use disorder: final evidence report and meeting summary1
- Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report1
- Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report1
- Insulin degludec (Tresiba®, Novo Nordisk A/S) for the treatment of diabetes: effectiveness, value, and value-based price benchmarks : final report1
- Integrating behavioral health into primary care: a technology assessment : final report1
- Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks : final report1
- Modulator treatments for cystic fibrosis: effectiveness and value1
- Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects: revised evidence report1
- Oral immunotherapy and Viaskin Peanut for peanut allergy: effectiveness and value : final evidence report1
- PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report1
- Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report1
- The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report1